Subgroups and Special Populations in Heart Failure Clinical Trials: Insights From the HFC-ARC Expert Consensus Panel

Area of Science:

• Cardiology
• Clinical Trials
• Genetics

Background:

• Heart failure (HF) management requires subgroup analysis in clinical trials for better decision-making.
• Heterogeneity in HF study outcomes necessitates standardized approaches.
• Expert collaboration involved academia, industry, FDA, and patient representatives.

Purpose of the Study:

• To propose standardized definitions and endpoints for HF subgroups and special populations in clinical trials.
• To enhance the precision, efficacy, and applicability of HF clinical research.
• To promote personalized interpretation of clinical trial results.

Main Methods:

• Collaborative development of definitions and endpoints by the Heart Failure Collaboratory and Academic Research Consortium.
• Focus on methodological considerations for subgroup analyses in large-scale trials.
• Exploration of gene therapy for genetic cardiomyopathies.

Main Results:

• Proposed standardized definitions and endpoints for HF subgroups and special populations.
• Highlighted best practices for interpreting subgroup analyses and identifying heterogeneity.
• Emphasized the need for validation of hypothesis-generating subgroup findings.

Conclusions:

• A methodical approach to clinical trial design, prioritizing subgroup identification and statistical rigor, is advocated.
• Standardized definitions and endpoints will improve the reliability and clinical relevance of HF trial findings.
• This framework aims to advance personalized and effective HF treatments, improving patient outcomes.